NS5B polymerase inhibitors in phase II clinical trials for HCV infection

  title={NS5B polymerase inhibitors in phase II clinical trials for HCV infection},
  author={Guglielmo Borgia and Alberto Enrico Maraolo and Salvatore Nappa and Ivan Gentile and Antonio Riccardo Buonomo},
  journal={Expert Opinion on Investigational Drugs},
  pages={243 - 250}
ABSTRACT Introduction: Hepatitis C virus (HCV) infection might be the first chronic viral disease to be eradicated without the introduction of a prophylactic vaccine. This is essentially due to therapeutic revolution encapsulated by the advent of direct-acting antivirals (DAA) agents, whose efficacy, safety and tolerability (all oral regimens) have made the previous standard of care (interferon plus ribavirin) a vestige of the past. The new regimens achieve very high response rates and have an… 
Hepatitis C virus genotype 3: clinical features, current and emerging viral inhibitors, future challenges
The clinical features associated with HCV genotype 3, current and emerging treatment regimens, and challenges associated with treatment are reviewed.
Discovery of Beclabuvir: A Potent Allosteric Inhibitor of the Hepatitis C Virus Polymerase
  • R. Gentles
  • Chemistry
    HCV: The Journey from Discovery to a Cure
  • 2018
The discovery of beclabuvir occurred through an iterative series of structure-activity relationship studies directed at the optimization of a novel class of indolobenzazepines, identified as having superior antiviral, safety, and pharmacokinetic properties.
Non-nucleoside structured compounds with antiviral activity—past 10 years (2010–2020)
Genetically Modified Mouse Mesenchymal Stem Cells Expressing Non-Structural Proteins of Hepatitis C Virus Induce Effective Immune Response
The first example that suggests the feasibility of using mMSCs for the development of an effective anti-HCV vaccine is suggested, associated with pronounced IL-6 secretion and reduction in the population of myeloid derived suppressor cells (MDSCs).
Genetically Modified Mouse Mesenchymal Stem Cells Expressing Non-Structural Proteins of Hepatitis C Virus Induce E ff ective Immune Response
The immunostimulatory activity of mMSCs was associated with pronounced IL-6 secretion and reduction in the population of myeloid derived suppressor cells (MDSCs), suggesting the feasibility of using m MSCs for the development of an anti-HCV vaccine.
Curing Hepatitis C with Direct‐Acting Antiviral Therapy
  • M. Sofia
  • Medicine
    New Drug Development for Known and Emerging Viruses
  • 2021


The therapeutic potential of new investigational hepatitis C virus translation inhibitors
This review summarizes pre-clinical and clinical data regarding HCV translation inhibitors, a new class of drugs currently in the pipeline with novel mechanisms of action, and suggests there is still room for new drugs in this setting, providing that they demonstrate an advantage in terms of efficacy, safety, cost or or simplicity of use.
Hepatitis C therapy with HCV NS5B polymerase inhibitors
Amongst HCV polymerase inhibitors, sofosbuvir has positioned as unique companion with ribavirin as therapy for most HCV genotypes 2 or 3, and along with NS5A inhibitors for other HCV Genotypes.
Investigational nucleoside and nucleotide polymerase inhibitors and their use in treating hepatitis C virus
This review focuses on investigational nucleoside or nucleotide inhibitors of viral polymerase that are potential treatments of HCV and reviews drugs that are currently under investigational status.
Investigational direct-acting antivirals in hepatitis C treatment: the latest drugs in clinical development
These new antivirals lead to high rates of viral eradication without relevant adverse reactions and seem to be effective regardless of viral genotypes, presence of resistant-associated variants or advanced liver disease, and chronic HCV-related hepatitis may become a curable disease.
Dasabuvir: A Non-Nucleoside Inhibitor of NS5B for the Treatment of Hepatitis C Virus Infection.
In combinations with other oral DAAs, dasabuvir results in very high rates of SVR in patients with HCV genotype 1 infection with a good tolerability and safety.
Future landscape of hepatitis C research - Basic, translational and clinical perspectives.
The discovery of sofosbuvir: a revolution for therapy of chronic hepatitis C
The authors analyze all of the main steps leading to the global approval of sofosbuvir, a direct-acting antiviral (DAAs) that represents the backbone of several effective regimens, in combination with IFN or with other DAAs (IFN-free therapies).
Dasabuvir (ABT333) for the treatment of chronic HCV genotype I: a new face of cure, an expert review
Dasabuvir is extensively evaluated in large clinical trials and shown excellent SVR among HCV genotype1 patient population in combination with other oral DAAs, with good safety profile and tolerance, and its drawback is its genotype restriction, need for ribavirin for 1a genotype, low resistance barrier and high cost.
Hepatitis C virus NS5A inhibitors and drug resistance mutations.
It is recommended that HCV NS5A inhibitors be used in combination regimens potent enough to prevent the emergence of resistant variants to help treat hepatitis C virus-infected patients.
Efficacy and Safety of Sofosbuvir in the Treatment of Chronic Hepatitis C: The Dawn of a New Era.
The recent phase III trials of sofosbuvir confirm the excellent results of phase II studies in terms of efficacy and safety and will probably open a new era in the fight against HCV.